Story perspectives

MindBio's LSD Microdosing Trial Raises Doubts on Depression Treatment

1/31/2026

50 6

Summary

Story summary

MindBio Therapeutics, an Australian company, reported a Phase 2B trial with 89 patients found LSD microdosing did not significantly improve major depressive disorder versus placebo (a caffeine pill).
MindBio CEO Justin Hanka described the results as potentially detrimental to microdosing.
Skeptical researchers say any perceived benefits may reflect the placebo effect rather than the drug.
The findings raise questions about microdosing as a depression treatment.

1 of 1

Story summary

MindBio Therapeutics, an Australian company, reported a Phase 2B trial with 89 patients found LSD microdosing did not significantly improve major depressive disorder versus placebo (a caffeine pill).
MindBio CEO Justin Hanka described the results as potentially detrimental to microdosing.
Skeptical researchers say any perceived benefits may reflect the placebo effect rather than the drug.
The findings raise questions about microdosing as a depression treatment.